Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
WNT1-inducible-signaling pathway protein 1 (WISP1), also known as CCN4, is a secreted matricellular protein belonging to the CCN family that plays a critical role in mediating cell-to-cell and cell-to-matrix communications. It is typically induced by the canonical Wnt/beta-catenin signaling pathway and serves as a key regulator of the extracellular matrix (ECM) environment, influencing cell proliferation, survival, and migration across various tissues. In healthy physiology, WISP1 is involved in embryonic development, bone turnover, and tissue repair; however, its pathological overexpression is strongly associated with the progression of fibrosis and cancer. In oncology, WISP1 acts as a pro-tumorigenic factor by promoting epithelial-mesenchymal transition (EMT), angiogenesis, and resistance to apoptosis in several malignancies, including gastric, breast, and lung cancers. In fibrotic diseases, such as idiopathic pulmonary fibrosis (IPF) and liver cirrhosis, WISP1 facilitates myofibroblast activation and excessive collagen deposition. Current therapeutic development focuses on neutralizing WISP1 with monoclonal antibodies to block its interaction with cell surface receptors, such as integrins and low-density lipoprotein receptor-related proteins (LRPs), thereby halting disease progression. Clinical candidates like MTX-463 are currently undergoing evaluation in trials for their potential to treat severe fibrotic conditions.
Neutralization of WISP1 protein to inhibit binding to integrins (e.g., alpha-v beta-3) and LRP receptors, thereby blocking downstream pro-fibrotic and pro-oncogenic signaling pathways.
1 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on WNT1-inducible-signaling pathway protein 1 (WISP1) (WISP1).